Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2001 May;51(5):423-8.
doi: 10.1046/j.1365-2125.2001.01387.x.

Concentration-effect relationships of two infusion rates of the imidazoline antihypertensive agent rilmenidine for blood pressure and development of side-effects in healthy subjects

S J de Visser  1 , J M van Gerven, R C Schoemaker, A F Cohen
Affiliations
Clinical Trial

Concentration-effect relationships of two infusion rates of the imidazoline antihypertensive agent rilmenidine for blood pressure and development of side-effects in healthy subjects

S J de Visser et al. Br J Clin Pharmacol. 2001 May.

Abstract

Aims: The aim of this study was to compare the effect profiles of i.v. administered rilmenidine aimed at the same target plasma concentration, but attained with different rates.

Methods: The study was placebo-controlled, randomized, double-blind, double-dummy, three-way, cross-over in nine healthy volunteers. All subjects randomly received either a fast infusion, a slow infusion or a placebo infusion. The target concentration was set at 8 ng ml-1 with a fivefold difference in the time to reach the maximum concentration. Saccadic eye movements, electroencephalography (EEG), blood pressure and heart rate were measured every half hour. Drug plasma concentrations, adverse events, salivary flow and visual analogue scales were obtained every hour.

Results: Changes in systolic/diastolic blood pressure at the end of the infusion were (mean +/- s.d.) 13.3 +/- 16.4/7.9 +/- 7.5 mmHg with the fast infusion and 16.3 +/- 12.7/10.2 +/- 7.9 mmHg during the slow infusion, compared with 0.0 +/- 13.2/1.3 +/- 8.3 mmHg for the placebo occasion. Decrease of saccadic peak velocity (SPV) at the end of the infusion was 18.0 +/- 5.2% during the fast infusion, 23.0 +/- 7.0% with the slow infusion, and 6.1 +/- 5.2% with placebo. PK/PD analysis showed similar concentration-dependent linear reduction in SPV and blood pressure up to the maximum observed rilmenidine plasma level for both the fast and the slow infusion.

Conclusions: The rate of infusion of rilmenidine in healthy volunteers does not influence the PK/PD relationship of saccadic eye movements and blood pressure up to the maximum observed rilmenidine plasma concentrations. Rilmenidine causes clear concentration-dependent blood pressure reductions in healthy volunteers.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Time-concentration profiles (mean + s.d.) for slow (•) and fast (○) rilmenidine infusions.
Figure 2
Figure 2
Time-effect profiles (mean + s.d.) for diastolic blood pressure for placebo (▪), slow (•) and fast (○) rilmenidine infusions.
Figure 3
Figure 3
Time-effect profiles (mean + s.d.) for saccadic peak velocity for placebo (▪), slow (•) and fast (○) rilmenidine infusions.
Figure 4
Figure 4
Time-effect profiles (mean + s.d.) for saliva production for placebo (▪), slow (•) and fast (○) rilmenidine infusions.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ostermann G, Brisgand B, Schmitt J, Fillastre J-P. Efficacy and acceptability of ril menidine for mild to moderate systemic hypertension. Am J Cardiol. 1988;61:76D–80D. - PubMed
    1. Fillastre J-P, Letac B, Galinier F, Le Bihan G, Schwartz J. A multicenter double-blind comparative study of rilmenidine and clonidine in 333 hypertensive patients. Am J Cardiol. 1988;61:81D–85D. - PubMed
    1. Galley P, Manciet G, Hessel J-L, Michel JP. Antihypertensive efficacy and acceptability of rilmenidine in elderly hypertensive patients. Am J Cardiol. 1988;61:86D–90D. - PubMed
    1. Mpoy M, Vandeleene B, Ketelslegers J-M, Lambert AE. Treatment of systemic hypertension in insulin-treated diabetes mellitus with rilmenidine. Am J Cardiol. 1988;61:91D–94D. - PubMed
    1. Beau B, Mahieux F, Paraire M, Laurin S, Brisgand B, Vitou P. Efficacy and safety of rilmenidine for arterial hypertension. Am J Cardiol. 1988;61:95D–101D. - PubMed

Publication types

MeSH terms